Boeing's Chief Executive has once again told the public his company will beat Elon Musk's SpaceX in its mission to Mars. Will Goodman, Managing Editor at Rockets are Cool, joins Cheddar to discuss the competition between the two aviation companies.
Boeing believes it will do a "slingshot" mission around the moon by 2019. However, NASA says that most likely won't happen and gives people a more realistic date of June 2020. Either company making it to Mars it really comes down to funding. Goodman talks about how much the flight will cost for each company.
Plus, SpaceX will attempt to re-launch both an orbital rocket and the Dragon spacecraft together for the first time on Tuesday. This will be a huge step for the company when it comes to reusing products, and Goodman talks about how much money it will save if successful.
Australia’s Great Barrier Reef is spawning in an explosion of color as the World Heritage-listed natural wonder recovers from life-threatening coral bleaching episodes.
Climate change that may have contributed to a lobster boom in Maine could soon lead to a bust. Chloe Aiello reports.
Good Morning America co-host Michael Strahan will be among the crew on Blue Origin’s next flight to space.
President Joe Biden is ordering a record-setting 50 million barrels of oil released from America's strategic reserve to help bring down energy costs.
All the news you Need2Know for Tuesday, November 23, 2021.
The U.S. is moving to open up COVID-19 booster shots to all adults, letting them choose another dose of either the Pfizer or Moderna vaccine.
U.S. health officials say an estimated 100,000 Americans died of drug overdoses in one year. That's a total the nation has never seen.
Russian officials on Tuesday rejected accusations that they endangered astronauts aboard the International Space Station by conducting a weapons test that created more than 1,500 pieces of space junk.
Austria has taken what its leader called the “dramatic” step of implementing a nationwide lockdown for unvaccinated people who haven’t recently had COVID-19.
Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joins the race to bring the first easy-to-use medication against the coronavirus to the U.S. market.
